Pharma M&A Deal Value Jumps 101% in Q1 2025, Fueled by Oncology Focus
Pharma mergers and acquisitions saw a significant increase in value during the first quarter of 2025, despite political uncertainty in the United States. A new report reveals deal value surged by 101% in this period, with oncology remaining the dominant therapeutic area. GlobalData’s report indicates that oncology assets were the primary target for most of the deals made during Q1 2025. This focus reflects the continued importance and investment in cancer-related research and development within the pharmaceutical industry.
Newsflash | Powered by GeneOnline AI
Date: May 2, 2025
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20